Top

Reactions Weekly

Published in:

01-04-2024 | Trastuzumab | Case report

Trastuzumab-deruxtecan

Interstitial lung disease and nausea

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Visani L, et al. Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients. European Journal of Cancer 200 (Suppl. 1): 60-61 abstr. 156 (PB-063) 156 (PB-063), Mar 2024. Available from: URL: https://dx.doi.org/10.1016/j.ejca.2024.113730 [abstract]

Title: Trastuzumab-deruxtecan
Interstitial lung disease and nausea
Publication date: 01-04-2024
Publisher: Springer International Publishing
Keywords: Trastuzumab
Breast Cancer
Breast Cancer
Nausea
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-55821-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Trastuzumab-deruxtecan

Interstitial lung disease and nausea

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Labetalol/Magnesium-sulfate

Glutathione

Ethinylestradiol/etonogestrel

Cyclophosphamide/fludarabine/ruxolitinib

Antiepileptic-drugs/cotrimoxazole

Ingenol-mebutate